Kinetic Modeling of PROTAC-Induced Protein Degradation

被引:4
|
作者
Zhao, Hongtao [1 ]
Narjes, Frank [1 ]
机构
[1] AstraZeneca, BioPharmaceut R&D, Resp & Immunol R&I, Med Chem Res & Early Dev, S-43183 Gothenburg, Sweden
关键词
PROTAC; protein degradation; ternary complex; ubiquitylation; kinetics;
D O I
10.1002/cmdc.202300530
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Kinetics of the PROTAC-induced protein degradation were modelled using the equilibrium approximation, accounting for the protein recovery rate with a time lag. The simulated kinetic curves resemble what is experimentally observed, and the physical formulas of the half-maximal degradation concentration (DC50) were derived from them. The equations reveal that DC50 is proportional to the dissociation constant of the ternary complex (Kd) and inversely proportional to the expression level of the E3 ligase and the effective ubiquitylation rate (kub). The predicted relationships were rigorously confirmed by experimental evidences from a matched molecular pair analysis using a set of published PROTACs. The equations derived from kinetic modelling of PROTAC-induced protein degradation reveal the dependency of DC50 on the dissociation constant of the ternary complex, the expression level of the E3 ligase, and the effective ubiquitylation rate.image
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Targeted Protein Degradation: Design Considerations for PROTAC Development
    Tran, Nathan L.
    Leconte, Georges A.
    Ferguson, Fleur M.
    CURRENT PROTOCOLS, 2022, 2 (12):
  • [22] Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism
    Tripodi, Armando
    Legnani, Cristina
    Lemma, Laura
    Cosmi, Benilde
    Palareti, Gualtiero
    Chantarangkul, Veena
    Mannucci, Pier Mannuccio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 30 (02) : 215 - 219
  • [23] PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
    Kelm, Jeremy M. M.
    Pandey, Deepti S. S.
    Malin, Evan
    Kansou, Hussein
    Arora, Sahil
    Kumar, Raj
    Gavande, Navnath S. S.
    MOLECULAR CANCER, 2023, 22 (01)
  • [24] Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
    Huifang Wang
    Runhua Zhou
    Fushan Xu
    Kongjun Yang
    Liuhai Zheng
    Pan Zhao
    Guangwei Shi
    Lingyun Dai
    Chengchao Xu
    Le Yu
    Zhijie Li
    Jianhong Wang
    Jigang Wang
    Biomaterials Research, 27
  • [25] From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
    Wang, Siqi
    He, Fuchu
    Tian, Chunyan
    Sun, Aihua
    PHARMACEUTICALS, 2024, 17 (01)
  • [26] Phase Separation Enhanced PROTAC for Highly Efficient Protein Degradation
    Yu, Xiaolin
    Hu, Wenrui
    Dong, Hang
    Zhao, Tian
    Wang, Xiaotian
    Chen, Long
    Xue, Song
    Li, Jin-Ping
    Luo, Shi-Zhong
    BIOMACROMOLECULES, 2024, 25 (07) : 4374 - 4383
  • [27] PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
    Qi, Si-Min
    Dong, Jinyun
    Xu, Zhi-Yuan
    Cheng, Xiang-Dong
    Zhang, Wei-Dong
    Qin, Jiang-Jiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [28] PROTAC-mediated protein degradation: New therapeutic modality
    Burslem, George
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [29] Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
    Wang, Huifang
    Zhou, Runhua
    Xu, Fushan
    Yang, Kongjun
    Zheng, Liuhai
    Zhao, Pan
    Shi, Guangwei
    Dai, Lingyun
    Xu, Chengchao
    Yu, Le
    Li, Zhijie
    Wang, Jianhong
    Wang, Jigang
    BIOMATERIALS RESEARCH, 2023, 27 (01)
  • [30] PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
    Jeremy M. Kelm
    Deepti S. Pandey
    Evan Malin
    Hussein Kansou
    Sahil Arora
    Raj Kumar
    Navnath S. Gavande
    Molecular Cancer, 22